Drug Shortage Report for MILRINONE LACTATE INJECTION, USP
| Report ID | 157676 |
| Drug Identification Number | 02244622 |
| Brand name | MILRINONE LACTATE INJECTION, USP |
| Common or Proper name | Milrinone Lactate Injection, USP |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | MILRINONE |
| Strength(s) | 1MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 20mL |
| ATC code | C01CE |
| ATC description | CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES |
| Reason for shortage | Demand increase for the drug. |
| Anticipated start date | |
| Actual start date | 2022-04-01 |
| Estimated end date | 2022-04-30 |
| Actual end date | 2022-04-30 |
| Shortage status | Resolved |
| Updated date | 2022-05-02 |
| Company comments | Effective Apr. 1, 2022, allocation of Milrinone Lactate Injection, USP 10mL increased to cover 100% of 10mL demand plus 50% of 20mL demand. Allocations of 20mL will be reduced to 50%. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2022-05-02 | French | Compare |
| v4 | 2022-05-02 | English | Compare |
| v3 | 2022-04-02 | English | Compare |
| v2 | 2022-03-31 | French | Compare |
| v1 | 2022-03-31 | English | Compare |
Showing 1 to 5 of 5